The Impact of an Adaptive Patient-centered Web Application on Medication Optimization in HFrEF Patients (SmartHF)
Heart Failure
About this trial
This is an interventional treatment trial for Heart Failure
Eligibility Criteria
Inclusion Criteria: Age 18 years and older at screening Diagnosis of heart failure with a left ventricular ejection fraction (LVEF) </= 40% (HFrEF) Have a general medicine provider or general cardiology provider for HFrEF Have internet access and access to their health system's patient portal Fluent in spoken and written English At least two of the following: systolic blood pressure ≥ 110mmg, potassium ≤ 5.5, serum creatinine ≤ 2.5, heart rate ≥ 70 At least two eligible heart failure therapies (guideline-recommended BB, RASI, MRA, or SGLT2i) not yet initiated or below 50% of the target dose Exclusion Criteria: End-stage HF (hospice candidate) Actively treated cancer, except non-melanoma skin cancer Implanted ventricular assist device Current treatment with chronic inotropic therapy Patient's provider for HFrEF care is considered an advanced HF specialist Currently pregnant or intends to become pregnant during the study period Dialysis
Sites / Locations
- Emory University, Grady Hospital
- University of MichiganRecruiting
- Henry Ford Hospital and Health System
- Washington University, Barns Jewish Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
SmartHF application
Control - Patients Standard Medication(s)
The web application-based study intervention provides adaptive medication recommendations that can be shared with their HF provider.
No change to current medication(s)